华润医药(03320.HK)中期纯利增长34.9%至30.35亿港元
格隆汇8月26日丨华润医药(03320.HK)公布，截至2019年6月30日止六个月，实现收益1019.23亿港元，同比增长8.7%；毛利174.34亿港元，同比增长3.27%；公司拥有人应占期内溢利30.35亿港元，同比增长34.9%；每股基本盈利0.48港元。
公告称，2019年上半年制药、医药分销、药品零售三个主要业务分部的收益占比分别为15.5%、81.5%以及2.9%。
制药业务方面，报告期间内集团制药业务实现分部收益173.67亿港元，较2018年上半年增长2.9%。
按产品类别划分，2019年上半年化学药品录得收益84.63亿港元，较上年同期增长5.3%，主要受益于慢病与专科用药的收益增加；中药录得收益74.87亿港元，同比基本持平，主要由于感冒、肠胃、骨科及心脑血管等多个品类的中药OTC产品与中药配方颗粒的收益增加，以及受益于并购江中药业股份有限公司带来的影响；生物药业务实现收益1.06亿港元，受营销体系优化影响较上年同期增长19.7%；营养保健品录得收益3.28亿港元，较上年同期上升7.0%。
截至2019年6月30日，集团的在研项目约200个，其中包括创新药在研项目45个，主要涉及心血管系统、代谢及内分泌、呼吸系统、肿瘤及免疫、精神神经系统、抗感染、血液、泌尿生殖系统等研发领域。报告期间内，集团获得专利授权38项，新申请专利47项，获得各级政府奖项及课题资金支持21项。
医药分销业务方面，2019年上半年，集团医药分销业务实现分部收益849.49亿港元，较2018年上半年增长9.5%。
截至2019年6月30日，集团医药分销网路已覆盖至全国28个省、直辖市及自治区，客户中包括二、三级医院6,862家，基层医疗机构53,640家，以及零售药房35,888家。
医药零售业务方面，集团医药零售业务录得收益29.46亿港元，同比增长19.2%。
截至2019年6月30日，集团共有842家零售药房。报告期间内，集团进一步加强品牌建设、零售门店布局；已完成集采系统平台搭建，并完成与浙江贝达、君实生物等厂家对接；积极开展DTP、慢病管理等创新业务模式，拓展电商业务、中医医疗及跨境购业务，与微信、京东等开展业务合作。报告期间末，DTP药房已达150家，覆盖中国76个城市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
